GLP-1s May Cut Cancer Risk, Slowing Progression in Recent Studies
Updated
Updated · NPR · Jun 9
GLP-1s May Cut Cancer Risk, Slowing Progression in Recent Studies
3 articles · Updated · NPR · Jun 9
Summary
Recent studies suggest GLP-1 drugs may both reduce cancer risk and slow disease progression, extending their potential benefits beyond diabetes control and weight loss.
Weight loss itself is already linked to lower cancer risk, but researchers say that alone may not explain the findings.
Scientists are now probing whether GLP-1s also act through brain and metabolic pathways that could help prevent cancers from developing or advancing.
The emerging evidence points to a broader medical role for the drugs, though the latest report centers on early research into why the apparent effect may occur.